(Q36895793)

16 August 2017

1 reference

title

Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma (English)

1 reference

16 August 2017

1

Patrick Schöffski

1 reference

16 August 2017

4

Raf Sciot

1 reference

16 August 2017

5

Ivo De Wever

1 reference

16 August 2017

7

Cristiana Stefan

1 reference

16 August 2017

8

Herlinde Dumez

1 reference

16 August 2017

Pascal Wolter

2

1 reference

16 August 2017

Paul Clement

series ordinal

3

1 reference

16 August 2017

Agnieszka Wozniak

series ordinal

6

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

381-392

1 reference

16 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Bisphosphonates for treatment and prevention of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

Targeting signal transduction pathways in colorectal cancer--more than skin deep

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.4.381

21 January 2018

Identifiers

DOI

10.2217/14796694.3.4.381

1 reference

release_f347blfqmzeo5cmboctnifvm7u

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f347blfqmzeo5cmboctnifvm7u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference